National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
about
PREDOSE: a semantic web platform for drug abuse epidemiology using social mediaTypologies of prescription opioid use in a large sample of adults assessed for substance abuse treatmentCurrent and future development of extended-release, abuse-deterrent opioid formulations in the United States.Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.Data Sources Regarding the Nonmedical Use of Pharmaceutical Opioids in the United States.Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis.Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.Strategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs.Geographic information systems and pharmacoepidemiology: using spatial cluster detection to monitor local patterns of prescription opioid abuse.Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.Role of key informants and direct patient interviews in epidemiological studies of substance abuse.Measures to quantify the abuse of prescription opioids: a review of data sources and metrics.Abuse risks and routes of administration of different prescription opioid compounds and formulations.Postmarketing surveillance for "modified-risk" tobacco productsPrescribers' expectations and barriers to electronic prescribing of controlled substances.Designing opioids that deter abuseResearch design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations."I just wanted to tell you that loperamide WILL WORK": a web-based study of extra-medical use of loperamide.Can abuse deterrent formulations make a difference? Expectation and speculation.Women who abuse prescription opioids: findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database.Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users.Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions.Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.Patterns of abuse and routes of administration for immediate-release hydrocodone combination products.Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure.Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration.Nonmedical use of prescription ADHD stimulant medications among adults in a substance abuse treatment population: early findings from the NAVIPPRO surveillance system.How did you know you got the right pill? Prescription opioid identification and measurement error in the abuse deterrent formulation era.Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter".A Brief Survey to Characterize Oxycodone Abuse Patterns in Adolescents Enrolled in Two Substance Abuse Recovery High Schools
P2860
Q28661407-5481A3B6-0EA7-4134-92B2-88756ABD7175Q28743202-FC7F1501-A673-4362-B6D3-9EAEE2DF8A41Q30240248-748144E4-C770-4B69-8CCE-5E49572B2395Q30677208-0B507057-9E53-4006-B0F8-957EBFEFF9B8Q30881147-124A9456-5375-4FCA-B680-F436BBDFD509Q31158757-40CB4D6E-3247-4681-9B02-9B7662BA45DCQ33685208-2A6359BD-0C95-4337-82D3-2EC0A551E34AQ33932344-989E0AE5-6739-4AFE-9F22-BF4362150FAAQ34158623-62100D4E-3299-435F-ADFA-3FF5FD3AE103Q34808676-3D797138-46FA-481C-94C7-46DD227AFB09Q34981568-E92BE8F4-BC25-496A-9B20-A91070632A50Q35278475-84506020-2EE6-4CEC-A650-4DB42A44906BQ35541054-BB66E5A7-354B-42EA-A1AD-F2664A968638Q35624464-2AA81179-798D-406D-B16A-868088E52174Q35926848-4136624F-7B4C-466A-8688-409E9CE0CDDDQ36415568-56DC907D-6188-439A-A1BE-13BFCAF84745Q36742039-BF3E82EC-2ADD-4FDC-8A4E-5EF3497E3877Q36788050-07B05407-B7BF-4F7D-BA5A-7F6BE2D4721BQ37223480-9024E207-C0EB-4314-8C8F-190E78A5E992Q37227555-74816BE8-FB60-44A3-9049-D39235DEDE69Q37265572-7427006F-2588-4C81-8616-7CFADF3C6A6DQ37616572-EBCE2F89-1C49-437C-A1B1-53B027AA9B59Q37616576-B5DFD98F-54F2-45AD-9C79-325D00E0C12FQ37862258-0FD4E005-FF6E-4301-AFA1-435631465339Q37868570-4C9D97AB-4A1E-4B8E-A011-0E2F2E18FE75Q38632934-0AB761FF-76D6-4329-94E8-504918295A47Q38644058-B23E1894-6F93-4FF9-8435-6D1A799068F8Q38683620-B8207A09-45A5-415A-9768-36CC95917BD8Q39037700-D78DB9D2-6E26-4434-A0E0-2B54E532F6E8Q42950103-6C4968E1-66FD-425B-B1A8-79C1AAB61369Q44329825-9B401508-050A-4289-A717-81A9E19A07CEQ44340245-C47946DF-2A9F-4385-A161-4E33CBD6CDE4Q44342495-847E114D-A1C7-4E3D-9917-261F26047578Q44349626-4B465DCA-6B4F-43EA-96DF-12E6E0C8BF91Q44349641-F1CC56F5-C15E-459E-9318-A044DEA0D785Q45887814-76087446-24EB-414D-8ABF-68583E4E526AQ46647455-3929D3AA-10B4-4437-932C-DC4596C86165Q48026600-E48A136A-577B-4D88-8070-A3E023B46FD7Q58243890-DE0E8915-3E86-40E0-99DC-42BB00E9AE51
P2860
National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
National addictions vigilance ...... oring prescription drug abuse.
@en
National addictions vigilance ...... oring prescription drug abuse.
@nl
type
label
National addictions vigilance ...... oring prescription drug abuse.
@en
National addictions vigilance ...... oring prescription drug abuse.
@nl
prefLabel
National addictions vigilance ...... oring prescription drug abuse.
@en
National addictions vigilance ...... oring prescription drug abuse.
@nl
P2093
P2860
P356
P1476
National addictions vigilance ...... oring prescription drug abuse.
@en
P2093
Andrea Licari
James C Benneyan
James Dickinson
Katherine Lioy
Nathaniel Katz
Simon H Budman
Theresa A Cassidy
Traci Craig Green
P2860
P304
P356
10.1002/PDS.1659
P577
2008-12-01T00:00:00Z